Abiopharma

Investor Presentation - Q1 2026 - Periodic report amendment

Financial statements as of 31.3.26 of the third fund for investments in multi-family housing in the US of the company

Ceased to be an interested party - Leon Recanati

Capital market presentation - Q1 202 summary

Change/cancellation of a purchase plan

The company’s liability balance as of 31.3.26, by maturity dates

Q1 report for 2026

Register of shareholders, changes and capital status – exercise of employee warrants

Notice of annual meeting for 6.7.26 – reappointments, terms of office, voting instrument

Appointment of director – Yoav Fridor, as of 31.5.26 – amendment of report